Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis.
Rebound of disease activity during pregnancy after withdrawal of fingolimod.
Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
Autophagic myelin destruction by schwann cells during wallerian degeneration and segmental demyelination.
SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
Efficient transdifferentiation of human adipose-derived stem cells into Schwann-like cells: A promise for treatment of demyelinating diseases.
Assessing upper limb function in multiple sclerosis.
In multiple sclerosis oligoclonal bands connect to peripheral B cell responses.
Neuropsychological Aspects of Childhood Multiple Sclerosis: An Overview.
Central and Peripheral Nervous System Demyelination Following Mycoplasma Pneumonia Infection With Review of Literature.
The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients.
Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
FDA approves first oral drug to reduce MS relapses
HLA-DRB1-DQB1 Haplotypes Confer Susceptibility and Resistance to Multiple Sclerosis in Sardinia.
Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients.
A Patient with Leiden V Mutation, Multiple Sclerosis, Psoriasis, and Sicca Syndrome: Could Celecoxib and Fingolimod Adversely Affect the Heart?
In vivo vs. ex vivo Magnetic Resonance Imaging In Mice.
B-Cell Depletion Abrogates T Cell-Mediated Demyelination in an Antibody-Nondependent Common Marmoset Experimental Autoimmune Encephalomyelitis Model.
Self-Reported Fatigue and Energy Cost During Walking Are Not Related in Patients With Multiple Sclerosis.
Pathophysiology of the brain extracellular matrix: a new target for remyelination.
Cyclophosphamide therapy in pediatric multiple sclerosis.
The genetic and environmental bases of complex human-disease: extending the utility of twin-studies.
Presumptive Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis after Natalizumab Therapy.
Natalizumab in relapsing-remitting multiple sclerosis.

Pages